Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Genome and Epigenome

Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs

Fang Fang, Horacio Cardenas, Hao Huang, Guanglong Jiang, Susan M. Perkins, Chi Zhang, Harold N. Keer, Yunlong Liu, Kenneth P. Nephew and Daniela Matei
Fang Fang
Medical Sciences, School of Medicine, Indiana University, Bloomington, Indiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Horacio Cardenas
Division of Gynecologic Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hao Huang
Division of Gynecologic Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guanglong Jiang
Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, Indiana.Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan M. Perkins
Department of Biostatistics, Indiana University, Indianapolis, Indiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chi Zhang
Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, Indiana.Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harold N. Keer
Astex Pharmaceuticals, Inc., Pleasanton, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yunlong Liu
Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, Indiana.Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth P. Nephew
Medical Sciences, School of Medicine, Indiana University, Bloomington, Indiana.Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, Indiana.Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: knephew@indiana.edudaniela.matei@northwestern.edu
Daniela Matei
Division of Gynecologic Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois.Jesse Brown VA Medical Center, Chicago, Illinois.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: knephew@indiana.edudaniela.matei@northwestern.edu
DOI: 10.1158/0008-5472.CAN-17-1492 Published February 2018
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

DNA methylation aberrations have been implicated in acquired resistance to platinum drugs in ovarian cancer. In this study, we elucidated an epigenetic signature associated with platinum drug resensitization that may offer utility in predicting the outcomes of patients who are coadministered a DNA methyltransferase inhibitor. The ovarian cancer specimens we analyzed were derived from a recent clinical trial that compared the responses of patients with recurrent platinum-resistant ovarian cancer who received carboplatin plus the DNA methyltransferase inhibitor guadecitabine or a standard-of-care chemotherapy regimen selected by the treating physician. Tumor biopsies or malignant ascites were collected from patients before treatment (day 1, cycle 1) or after treatment (after 2 cycles) for epigenomic and transcriptomic profiling using the Infinium HumanMethylation450 BeadChip (HM450). We defined 94 gene promoters that were hypomethylated significantly by guadecitabine, with 1,659 genes differentially expressed in pretreatment versus posttreatment tumors. Pathway analysis revealed that the experimental regimen significantly altered immune reactivation and DNA repair pathways. Progression-free survival correlated with baseline expression levels of 1,155 genes involved in 25 networks. In functional investigations in ovarian cancer cells, engineered upregulation of certain signature genes silenced by promoter methylation (DOK2, miR-193a, and others) restored platinum drug sensitivity. Overall, our findings illuminate how inhibiting DNA methylation can sensitize ovarian cancer cells to platinum drugs, in large part by altering gene expression patterns related to DNA repair and immune activation, with implications for improving the personalized care and survival outcomes of ovarian cancer patients.

Significance: Epigenomic targeting may improve therapeutic outcomes in platinum-resistant and recurrent ovarian cancer in part by effects on DNA repair and antitumor immune responses. Cancer Res; 78(3); 631–44. ©2017 AACR.

Footnotes

  • Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

  • Prior presentations: This study was presented in part at the 2015 American Society of Clinical Oncology Annual Meeting and at the 2014 American Association for Cancer Research Meeting.

  • Received June 9, 2017.
  • Revision received September 13, 2017.
  • Accepted November 30, 2017.
  • ©2017 American Association for Cancer Research.
View Full Text

Log in using your username and password

Forgot your user name or password?

Purchase Short Term Access

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top
Cancer Research: 78 (3)
February 2018
Volume 78, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs
Fang Fang, Horacio Cardenas, Hao Huang, Guanglong Jiang, Susan M. Perkins, Chi Zhang, Harold N. Keer, Yunlong Liu, Kenneth P. Nephew and Daniela Matei
Cancer Res February 1 2018 (78) (3) 631-644; DOI: 10.1158/0008-5472.CAN-17-1492

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs
Fang Fang, Horacio Cardenas, Hao Huang, Guanglong Jiang, Susan M. Perkins, Chi Zhang, Harold N. Keer, Yunlong Liu, Kenneth P. Nephew and Daniela Matei
Cancer Res February 1 2018 (78) (3) 631-644; DOI: 10.1158/0008-5472.CAN-17-1492
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Patients and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • SLC25A11 Gene Mutations in Metastatic Paragangliomas
  • Regulatory Genomics of GWAS SNPs
  • Bivalent Chromatin and Acquired HGSOC CpG Methylation
Show more Genome and Epigenome
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement